Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.93
MKGAY's Cash to Debt is ranked higher than
68% of the 1159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.17 vs. MKGAY: 0.93 )
MKGAY' s 10-Year Cash to Debt Range
Min: 0.59   Max: No Debt
Current: 0.93

Equity to Asset 0.45
MKGAY's Equity to Asset is ranked higher than
57% of the 1084 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MKGAY: 0.45 )
MKGAY' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.61
Current: 0.45

0.27
0.61
F-Score: 6
Z-Score: 2.02
M-Score: -2.47
WACC vs ROIC
7.48%
22.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.87
MKGAY's Operating margin (%) is ranked higher than
85% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. MKGAY: 15.87 )
MKGAY' s 10-Year Operating margin (%) Range
Min: 2.84   Max: 19.54
Current: 15.87

2.84
19.54
Net-margin (%) 10.70
MKGAY's Net-margin (%) is ranked higher than
80% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MKGAY: 10.70 )
MKGAY' s 10-Year Net-margin (%) Range
Min: 2.91   Max: 49.88
Current: 10.7

2.91
49.88
ROE (%) 21.24
MKGAY's ROE (%) is ranked higher than
92% of the 1139 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.62 vs. MKGAY: 21.24 )
MKGAY' s 10-Year ROE (%) Range
Min: 3.97   Max: 56.87
Current: 21.24

3.97
56.87
ROA (%) 10.77
MKGAY's ROA (%) is ranked higher than
90% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.52 vs. MKGAY: 10.77 )
MKGAY' s 10-Year ROA (%) Range
Min: 2.33   Max: 30.58
Current: 10.77

2.33
30.58
ROC (Joel Greenblatt) (%) 98.61
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. MKGAY: 98.61 )
MKGAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.06   Max: 53.26
Current: 98.61

8.06
53.26
Revenue Growth (3Y)(%) 3.80
MKGAY's Revenue Growth (3Y)(%) is ranked higher than
68% of the 940 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MKGAY: 3.80 )
MKGAY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 15.8
Current: 3.8

0
15.8
EBITDA Growth (3Y)(%) 4.60
MKGAY's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 851 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MKGAY: 4.60 )
MKGAY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 14
Current: 4.6

0
14
EPS Growth (3Y)(%) 24.20
MKGAY's EPS Growth (3Y)(%) is ranked higher than
88% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MKGAY: 24.20 )
MKGAY' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.5   Max: 51.8
Current: 24.2

-25.5
51.8
» MKGAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.00
MKGAY's P/E(ttm) is ranked higher than
91% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. MKGAY: 18.00 )
MKGAY' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 261.35
Current: 18

10.19
261.35
Forward P/E 6.29
MKGAY's Forward P/E is ranked higher than
99% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 6.29 )
N/A
PE(NRI) 19.10
MKGAY's PE(NRI) is ranked higher than
92% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.20 vs. MKGAY: 19.10 )
MKGAY' s 10-Year PE(NRI) Range
Min: 10.19   Max: 261.35
Current: 19.1

10.19
261.35
P/B 1.10
MKGAY's P/B is ranked higher than
93% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. MKGAY: 1.10 )
MKGAY' s 10-Year P/B Range
Min: 0.35   Max: 1.22
Current: 1.1

0.35
1.22
P/S 3.69
MKGAY's P/S is ranked higher than
64% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. MKGAY: 3.69 )
MKGAY' s 10-Year P/S Range
Min: 0.59   Max: 7.96
Current: 3.69

0.59
7.96
PFCF 20.80
MKGAY's PFCF is ranked higher than
91% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3458.60 vs. MKGAY: 20.80 )
MKGAY' s 10-Year PFCF Range
Min: 5.92   Max: 24.05
Current: 20.8

5.92
24.05
POCF 17.03
MKGAY's POCF is ranked higher than
88% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.77 vs. MKGAY: 17.03 )
MKGAY' s 10-Year POCF Range
Min: 3.04   Max: 17.86
Current: 17.03

3.04
17.86
EV-to-EBIT 3.92
MKGAY's EV-to-EBIT is ranked higher than
99% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.13 vs. MKGAY: 3.92 )
MKGAY' s 10-Year EV-to-EBIT Range
Min: 2.9   Max: 114.2
Current: 3.92

2.9
114.2
Shiller P/E 37.00
MKGAY's Shiller P/E is ranked higher than
88% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 37.00 )
MKGAY' s 10-Year Shiller P/E Range
Min: 10.43   Max: 43.06
Current: 37

10.43
43.06
Current Ratio 1.59
MKGAY's Current Ratio is ranked higher than
62% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. MKGAY: 1.59 )
MKGAY' s 10-Year Current Ratio Range
Min: 0.85   Max: 2.24
Current: 1.59

0.85
2.24
Quick Ratio 1.34
MKGAY's Quick Ratio is ranked higher than
66% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MKGAY: 1.34 )
MKGAY' s 10-Year Quick Ratio Range
Min: 0.53   Max: 1.62
Current: 1.34

0.53
1.62
Days Inventory 86.53
MKGAY's Days Inventory is ranked higher than
86% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.39 vs. MKGAY: 86.53 )
MKGAY' s 10-Year Days Inventory Range
Min: 162.19   Max: 272.47
Current: 86.53

162.19
272.47
Days Sales Outstanding 36.18
MKGAY's Days Sales Outstanding is ranked higher than
92% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.94 vs. MKGAY: 36.18 )
MKGAY' s 10-Year Days Sales Outstanding Range
Min: 58.87   Max: 102.54
Current: 36.18

58.87
102.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.99
MKGAY's Dividend Yield is ranked lower than
56% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.32 vs. MKGAY: 0.99 )
MKGAY' s 10-Year Dividend Yield Range
Min: 0.85   Max: 5.19
Current: 0.99

0.85
5.19
Dividend Payout 0.36
MKGAY's Dividend Payout is ranked higher than
83% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 0.36 )
MKGAY' s 10-Year Dividend Payout Range
Min: 0.25   Max: 1.79
Current: 0.36

0.25
1.79
Dividend growth (3y) 15.00
MKGAY's Dividend growth (3y) is ranked higher than
84% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MKGAY: 15.00 )
MKGAY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 32.2
Current: 15

0
32.2
Yield on cost (5-Year) 1.06
MKGAY's Yield on cost (5-Year) is ranked lower than
56% of the 693 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. MKGAY: 1.06 )
MKGAY' s 10-Year Yield on cost (5-Year) Range
Min: 0.9   Max: 5.51
Current: 1.06

0.9
5.51

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 37.30
MKGAY's Price/Tangible Book is ranked lower than
59% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MKGAY: 37.30 )
MKGAY' s 10-Year Price/Tangible Book Range
Min: 1.41   Max: 24.9
Current: 37.3

1.41
24.9
Price/DCF (Projected) 1.90
MKGAY's Price/DCF (Projected) is ranked higher than
90% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 1.90 )
MKGAY' s 10-Year Price/DCF (Projected) Range
Min: 1.05   Max: 1.74
Current: 1.9

1.05
1.74
Price/Median PS Value 1.10
MKGAY's Price/Median PS Value is ranked higher than
89% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MKGAY: 1.10 )
MKGAY' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 1.09
Current: 1.1

0.26
1.09
Price/Peter Lynch Fair Value 0.70
MKGAY's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 0.70 )
MKGAY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 4.07
Current: 0.7

0.48
4.07
Price/Graham Number 4.30
MKGAY's Price/Graham Number is ranked higher than
71% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MKGAY: 4.30 )
MKGAY' s 10-Year Price/Graham Number Range
Min: 0.48   Max: 4.64
Current: 4.3

0.48
4.64
Earnings Yield (Greenblatt) 27.20
MKGAY's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MKGAY: 27.20 )
MKGAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 34.9
Current: 27.2

0.9
34.9
Forward Rate of Return (Yacktman) 40.89
MKGAY's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.86 vs. MKGAY: 40.89 )
MKGAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7   Max: 52.4
Current: 40.89

7
52.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:0NZZ, TKPYY, TEVA, AGN, FRX » details
Traded in other countries:0O14.UK, MER.Switzerland, MRK.Germany,
Merck KGaA is a pharmaceutical and chemical company founded in 1668 in Darmstadt. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. The Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for OTCPK:MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Paul T. Anastas Awarded Emanuel Merck Lectureship 2015 Apr 30 2015
Merck Millipore Introduces Magna ChIRP™ RNA Interactome Kits for the Analysis of... Apr 27 2015
Merck Wins German Innovation Award with Liquid Crystals Apr 25 2015
Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with... Apr 20 2015
Merck Demonstrates Commitment to Corporate Responsibility Apr 20 2015
Annual General Meeting Approves Dividend Increase Apr 17 2015
Merck Proposes Dividend Increase to AGM After a Year of Key Strategic Moves – Foundation Set for... Apr 17 2015
Alise Reicin Joins Merck Serono as Head of Global Clinical Development Apr 16 2015
Merck Serono’s Saizen Liquid can now be Stored up to one Week at Room Temperature Apr 15 2015
“Living Innovation”: Merck at the European Coatings Show 2015 Apr 15 2015
Merck Appoints Udit Batra to Head Combined Life Science Business Following Pending Sigma-Aldrich... Apr 13 2015
Not intended for UK-based media Global Strategic Partners Merck and Pfizer Finalize Agreement to... Apr 07 2015
Merck Serono and Medicines for Malaria Venture Sign Agreement to Develop Potential Antimalarial... Apr 01 2015
Innovations and Concepts with Added Value: Merck at the in-cosmetics 2015 Trade Show Mar 31 2015
Norcraft and Auspex are big market movers Mar 30 2015
Norcraft and Auspex are big market movers Mar 30 2015
Merck Presents Future Innovations with the 3D Tour “Create the Future” Mar 30 2015
Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T... Mar 30 2015
Merck Wins 2015 German Industry Innovation Award Mar 22 2015
Merck Supports Schistosomiasis Education in Mozambique Mar 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK